Owen J T Mccarty

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2146037/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	GPVI and integrin alphallbbeta3 signaling in platelets. Journal of Thrombosis and Haemostasis, 2005, 3, 1752-1762.	3.8	374
2	A role for factor XIIa–mediated factor XI activation in thrombus formation in vivo. Blood, 2010, 116, 3981-3989.	1.4	227
3	Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood, 2000, 96, 1789-1797.	1.4	196
4	Rac1 Is Essential for Platelet Lamellipodia Formation and Aggregate Stability under Flow. Journal of Biological Chemistry, 2005, 280, 39474-39484.	3.4	196
5	Ibrutinibâ€associated bleeding: pathogenesis, management and risk reduction strategies. Journal of Thrombosis and Haemostasis, 2017, 15, 835-847.	3.8	191
6	Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood, 2014, 123, 1739-1746.	1.4	187
7	Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood, 2009, 113, 936-944.	1.4	182
8	Single Molecule Characterization of P-selectin/Ligand Binding. Journal of Biological Chemistry, 2003, 278, 10556-10561.	3.4	167
9	Rho GTPases in platelet function. Journal of Thrombosis and Haemostasis, 2013, 11, 35-46.	3.8	146
10	Polyphosphate nanoparticles on the platelet surface trigger contact system activation. Blood, 2017, 129, 1707-1717.	1.4	121
11	Thrombosis and Bleeding in Extracorporeal Membrane Oxygenation (ECMO) Without Anticoagulation: A Systematic Review. ASAIO Journal, 2021, 67, 290-296.	1.6	115
12	S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation. Blood, 2011, 118, 3129-3136.	1.4	112
13	Microfluidics and Coagulation Biology. Annual Review of Biomedical Engineering, 2013, 15, 283-303.	12.3	110
14	Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. Blood, 2012, 119, 4762-4768.	1.4	86
15	Activated protein C inhibits neutrophil extracellular trap formation in vitro and activation in vivo. Journal of Biological Chemistry, 2017, 292, 8616-8629.	3.4	84
16	Evaluation of the role of platelet integrins in fibronectin-dependent spreading and adhesion. Journal of Thrombosis and Haemostasis, 2004, 2, 1823-1833.	3.8	81
17	Factor XII promotes blood coagulation independent of factor XI in the presence of longâ \in chain polyphosphates. Journal of Thrombosis and Haemostasis, 2013, 11, 1341-1352.	3.8	76
18	The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis. Frontiers in Oncology, 2018, 8, 78.	2.8	73

#	Article	IF	CITATIONS
19	Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: Implications for the oncoprotein c-MYC. American Journal of Physiology - Cell Physiology, 2017, 312, C176-C189.	4.6	71
20	Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 799-809.	2.4	68
21	Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function. American Journal of Physiology - Cell Physiology, 2016, 310, C373-C380.	4.6	62
22	The hemostatic role of factor XI. Thrombosis Research, 2016, 141, S8-S11.	1.7	60
23	Capture of Flowing Endothelial Cells Using Surface-Immobilized Anti-Kinase Insert Domain Receptor Antibody. Tissue Engineering - Part C: Methods, 2008, 14, 97-105.	2.1	59
24	Fluid Shear Regulates the Kinetics and Molecular Mechanisms of Activation-Dependent Platelet Binding to Colon Carcinoma Cells. Biophysical Journal, 2002, 83, 836-848.	0.5	58
25	Platelet Mechanotransduction. Annual Review of Biomedical Engineering, 2018, 20, 253-275.	12.3	57
26	Laminin promotes coagulation and thrombus formation in a factor Xllâ€dependent manner. Journal of Thrombosis and Haemostasis, 2010, 8, 1295-1301.	3.8	56
27	The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood, 2021, 138, 2173-2184.	1.4	56
28	Myosinlla contractility is required for maintenance of platelet structure during spreading on collagen and contributes to thrombus stability. Journal of Thrombosis and Haemostasis, 2007, 5, 2136-2145.	3.8	55
29	A physical sciences network characterization of circulating tumor cell aggregate transport. American Journal of Physiology - Cell Physiology, 2015, 308, C792-C802.	4.6	54
30	von Willebrand factor mediates platelet spreading through glycoprotein Ib and alphallbbeta3 in the presence of botrocetin and ristocetin, respectively. Journal of Thrombosis and Haemostasis, 2006, 4, 1367-1378.	3.8	53
31	Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs. Blood, 2020, 136, 2346-2358.	1.4	53
32	Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor. Blood, 2015, 125, 1488-1496.	1.4	51
33	Plasma contact factors as therapeutic targets. Blood Reviews, 2018, 32, 433-448.	5.7	50
34	Inhibition of contact-mediated activation of factor XI protects baboons against S aureus–induced organ damage and death. Blood Advances, 2019, 3, 658-669.	5.2	50
35	Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood, 2007, 109, 3733-3740.	1.4	49
36	Factor XI Deficiency Alters the Cytokine Response and Activation of Contact Proteases during Polymicrobial Sepsis in Mice. PLoS ONE, 2016, 11, e0152968.	2.5	49

#	Article	IF	CITATIONS
37	The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials. Seminars in Thrombosis and Hemostasis, 2019, 45, 502-508.	2.7	49
38	Aspirin and antiplatelet treatments in cancer. Blood, 2021, 137, 3201-3211.	1.4	49
39	Neonatal platelets: mediators of primary hemostasis in the developing hemostatic system. Pediatric Research, 2014, 76, 230-237.	2.3	48
40	The role of coagulation and platelets in colon cancer-associated thrombosis. American Journal of Physiology - Cell Physiology, 2019, 316, C264-C273.	4.6	48
41	Identification of a novel, actin-rich structure, the actin nodule, in the early stages of platelet spreading. Journal of Thrombosis and Haemostasis, 2008, 6, 1944-1952.	3.8	47
42	Preferential binding of platelets to monocytes over neutrophils under flow. Biochemical and Biophysical Research Communications, 2005, 329, 345-355.	2.1	42
43	Pak2 restrains endomitosis during megakaryopoiesis and alters cytoskeleton organization. Blood, 2015, 125, 2995-3005.	1.4	42
44	The PAK system links Rho GTPase signaling to thrombin-mediated platelet activation. American Journal of Physiology - Cell Physiology, 2013, 305, C519-C528.	4.6	41
45	Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer. Convergent Science Physical Oncology, 2017, 3, 023001.	2.6	38
46	Dynamics of Blood Flow and Thrombus Formation in a Multi-Bypass Microfluidic Ladder Network. Cellular and Molecular Bioengineering, 2017, 10, 16-29.	2.1	37
47	Nucleic acids as cofactors for factor XI and prekallikrein activation: Different roles for high-molecular-weight kininogen. Thrombosis and Haemostasis, 2017, 117, 671-681.	3.4	36
48	p21 Activated Kinase Signaling Coordinates Glycoprotein Receptor Vl–Mediated Platelet Aggregation, Lamellipodia Formation, and Aggregate Stability Under Shear. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1544-1551.	2.4	34
49	Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va. Blood, 2016, 128, 1870-1878.	1.4	34
50	The contact activation system as a potential therapeutic target in patients with COVIDâ€19. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 500-505.	2.3	33
51	Heat shock protein 70 regulates platelet integrin activation, granule secretion and aggregation. American Journal of Physiology - Cell Physiology, 2016, 310, C568-C575.	4.6	31
52	Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1748-1760.	2.4	30
53	The thrombotic potential of circulating tumor microemboli: computational modeling of circulating tumor cell-induced coagulation. American Journal of Physiology - Cell Physiology, 2015, 308, C229-C236.	4.6	29
54	Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 205-216.	2.3	29

#	Article	IF	CITATIONS
55	Exogenous eosinophil activation converts PSGL-1-dependent binding to CD18-dependent stable adhesion to platelets in shear flow. American Journal of Physiology - Cell Physiology, 2003, 284, C1223-C1234.	4.6	28
56	Coagulation Factor XI Promotes Distal Platelet Activation and Single Platelet Consumption in the Bloodstream Under Shear Flow. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 510-517.	2.4	28
57	The contact pathway and sepsis. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 331-339.	2.3	28
58	Dimensional analysis and scaling relevant to flow models of thrombus formation: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 619-622.	3.8	27
59	Protease-activated receptor 4 activity promotes platelet granule release and platelet-leukocyte interactions. Platelets, 2019, 30, 126-135.	2.3	27
60	Platelet-Derived Short-Chain Polyphosphates Enhance the Inactivation of Tissue Factor Pathway Inhibitor by Activated Coagulation Factor XI. PLoS ONE, 2016, 11, e0165172.	2.5	26
61	Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in lowâ€density lipoprotein receptorâ€deficient mice. Journal of Thrombosis and Haemostasis, 2021, 19, 1001-1017.	3.8	26
62	A Temporal Examination of Platelet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patients. Scientific Reports, 2018, 8, 6564.	3.3	25
63	Activated factor XI inhibits chemotaxis of polymorphonuclear leukocytes. Journal of Leukocyte Biology, 2011, 90, 923-927.	3.3	24
64	Cross-Talk between the Complement Pathway and the Contact Activation System of Coagulation: Activated Factor XI Neutralizes Complement Factor H. Journal of Immunology, 2021, 206, 1784-1792.	0.8	24
65	Measurement Science in the Circulatory System. Cellular and Molecular Bioengineering, 2014, 7, 1-14.	2.1	23
66	Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT mice. Blood Advances, 2019, 3, 3080-3091.	5.2	22
67	Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function. American Journal of Physiology - Cell Physiology, 2021, 320, C902-C915.	4.6	22
68	Assessment of roles for the Rho-specific guanine nucleotide dissociation inhibitor Ly-GDI in platelet function: a spatial systems approach. American Journal of Physiology - Cell Physiology, 2017, 312, C527-C536.	4.6	21
69	Endothelial PAI-1 (Plasminogen Activator Inhibitor-1) Blocks the Intrinsic Pathway of Coagulation, Inducing the Clearance and Degradation of FXIa (Activated Factor XI). Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1390-1401.	2.4	21
70	Network signatures of nuclear and cytoplasmic density alterations in a model of pre and postmetastatic colorectal cancer. Journal of Biomedical Optics, 2014, 19, 016016.	2.6	20
71	Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsis. Journal of Thrombosis and Haemostasis, 2020, 18, 180-190.	3.8	20
72	Platelet procoagulant phenotype is modulated by a p38-MK2 axis that regulates RTN4/Nogo proximal to the endoplasmic reticulum: utility of pathway analysis. American Journal of Physiology - Cell Physiology, 2018, 314, C603-C615.	4.6	18

#	Article	IF	CITATIONS
73	The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis. Platelets, 2022, 33, 66-72.	2.3	18
74	Assessment of neonatal, cord, and adult platelet granule trafficking and secretion. Platelets, 2020, 31, 68-78.	2.3	17
75	Regulation of the mTOR-Rac1 axis in platelet function. Small GTPases, 2012, 3, 67-70.	1.6	15
76	Potentiation of TRAP-6-induced platelet dense granule release by blockade of P2Y ₁₂ signaling with MRS2395. Platelets, 2018, 29, 383-394.	2.3	15
77	Factor XII plays a pathogenic role in organ failure and death in baboons challenged with <i>Staphylococcus aureus</i> . Blood, 2021, 138, 178-189.	1.4	15
78	The role of carrier number on the procoagulant activity of tissue factor in blood and plasma. Physical Biology, 2011, 8, 066005.	1.8	14
79	Removal of the C-Terminal Domains of ADAMTS13 by Activated Coagulation Factor XI induces Platelet Adhesion on Endothelial Cells under Flow Conditions. Frontiers in Medicine, 2017, 4, 232.	2.6	14
80	Regulation of immune cell signaling by activated protein C. Journal of Leukocyte Biology, 2018, 103, 1197-1203.	3.3	14
81	Model for surface-dependent factor XII activation: the roles of factor XII heavy chain domains. Blood Advances, 2022, 6, 3142-3154.	5.2	14
82	Revised model of the tissue factor pathway of thrombin generation: Role of the feedback activation of FXI. Journal of Thrombosis and Haemostasis, 2022, 20, 1350-1363.	3.8	14
83	Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function. Platelets, 2022, 33, 404-415.	2.3	13
84	Rational Design of an Ex Vivo Model of Thrombosis. Cellular and Molecular Bioengineering, 2010, 3, 187-189.	2.1	12
85	Carpe low-dose aspirin: the new anti-cancer face of an old anti-platelet drug. Platelets, 2018, 29, 773-778.	2.3	12
86	Development of Coagulation Factor XII Antibodies for Inhibiting Vascular Device-Related Thrombosis. Cellular and Molecular Bioengineering, 2021, 14, 161-175.	2.1	12
87	Role of platelets in regulating activated coagulation factor XI activity. American Journal of Physiology - Cell Physiology, 2021, 320, C365-C374.	4.6	12
88	The Toll-Like Receptor 2 Ligand Pam2CSK4 Activates Platelet Nuclear Factor-κB and Bruton's Tyrosine Kinase Signaling to Promote Platelet-Endothelial Cell Interactions. Frontiers in Immunology, 2021, 12, 729951.	4.8	12
89	Effects of ex vivo blood anticoagulation and preanalytical processing time on the proteome content of platelets. Journal of Thrombosis and Haemostasis, 2022, 20, 1437-1450.	3.8	12
90	Differential Roles for the Coagulation Factors XI and XII in Regulating the Physical Biology of Fibrin. Annals of Biomedical Engineering, 2017, 45, 1328-1340.	2.5	11

#	Article	IF	CITATIONS
91	Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?. Platelets, 2019, 30, 796-798.	2.3	11
92	Irreversible alteration of extracellular vesicle and cell-free messenger RNA profiles in human plasma associated with blood processing and storage. Scientific Reports, 2022, 12, 2099.	3.3	11
93	Utility of microfluidic devices to study the platelet–endothelium interface. Platelets, 2017, 28, 449-456.	2.3	10
94	Ticagrelor breaks up the tumor-platelet party. Blood, 2017, 130, 1177-1178.	1.4	10
95	Design and Utility of a Point-of-Care Microfluidic Platform to Assess Hematocrit and Blood Coagulation. Cellular and Molecular Bioengineering, 2018, 11, 519-529.	2.1	10
96	Severe thrombocytopenia in adults undergoing extracorporeal membrane oxygenation is predictive of thrombosis. Platelets, 2022, 33, 570-576.	2.3	10
97	Innovation, entrepreneurship, promotion, and tenure. Science, 2021, 373, 1312-1314.	12.6	10
98	Physiological levels of blood coagulation factors IX and X control coagulation kinetics in an <i>in vitro</i> model of circulating tissue factor. Physical Biology, 2013, 10, 036003.	1.8	9
99	Rac and Cdc42 team up for platelets. Blood, 2013, 122, 3096-3097.	1.4	9
100	A non irculating pool of factor XI associated with glycosaminoglycans in mice. Journal of Thrombosis and Haemostasis, 2019, 17, 1449-1460.	3.8	9
101	Evaluation of the Effect of Crosslinking Method of Poly(Vinyl Alcohol) Hydrogels on Thrombogenicity. Cardiovascular Engineering and Technology, 2020, 11, 448-455.	1.6	9
102	The basement membrane protein nidogen-1 supports platelet adhesion and activation. Platelets, 2021, 32, 424-428.	2.3	9
103	Heparin Resistance Is Common in Patients Undergoing Extracorporeal Membrane Oxygenation but Is Not Associated with Worse Clinical Outcomes. ASAIO Journal, 2021, 67, 899-906.	1.6	9
104	Thrombin generation and activity in multiple sclerosis. Metabolic Brain Disease, 2021, 36, 407-420.	2.9	9
105	CXCR7 expression disrupts endothelial cell homeostasis and causes ligand-dependent invasion. Cell Adhesion and Migration, 2014, 8, 165-176.	2.7	8
106	Development of a Method to Quantify Platelet Adhesion and Aggregation Under Static Conditions. Cellular and Molecular Bioengineering, 2014, 7, 285-290.	2.1	8
107	Effect of Ionizing Radiation on the Physical Biology of Head and Neck Squamous Cell Carcinoma Cells. Cellular and Molecular Bioengineering, 2015, 8, 517-525.	2.1	8
108	Utility and development of microfluidic platforms for platelet research. Platelets, 2017, 28, 425-426.	2.3	8

#	Article	IF	CITATIONS
109	The protein C activator AB002 rapidly interrupts thrombus development in baboons. Blood, 2020, 135, 689-699.	1.4	8
110	Pharmacological reduction of coagulation factor XI reduces macrophage accumulation and accelerates deep vein thrombosis resolution in a mouse model of venous thrombosis. Journal of Thrombosis and Haemostasis, 2022, 20, 2035-2045.	3.8	8
111	Modeling the effect of blood vessel bifurcation ratio on occlusive thrombus formation. Computer Methods in Biomechanics and Biomedical Engineering, 2019, 22, 972-980.	1.6	7
112	Identification, Quantification, and System Analysis of Protein Nâ€îµ Lysine Methylation in Anucleate Blood Platelets. Proteomics, 2019, 19, e1900001.	2.2	7
113	Rho GTPase regulation of reactive oxygen species generation and signalling in platelet function and disease. Small GTPases, 2021, 12, 440-457.	1.6	7
114	Evaluation of Platelet Antagonists in In Vitro Flow Models of Thrombosis. , 2004, 93, 21-34.		6
115	Biorheology of Platelet Activation in the Bloodstream Distal to Thrombus Formation. Cellular and Molecular Bioengineering, 2016, 9, 496-508.	2.1	6
116	Design of a Microfluidic Bleeding Chip to Evaluate Antithrombotic Agents for Use in COVID-19 Patients. Cellular and Molecular Bioengineering, 2020, 13, 331-339.	2.1	6
117	TRPing out Platelet Calcium. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 285-286.	2.4	5
118	Basic science research opportunities in thrombosis and hemostasis: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2022, 20, 1496-1506.	3.8	5
119	Ibrutinib Inhibits BMX-Dependent Endothelial VCAM-1 Expression In Vitro and Pro-Atherosclerotic Endothelial Activation and Platelet Adhesion In Vivo. Cellular and Molecular Bioengineering, 2022, 15, 231-243.	2.1	5
120	Chronic edible dosing of Δ9-tetrahydrocannabinol (THC) in nonhuman primates reduces systemic platelet activity and function. American Journal of Physiology - Cell Physiology, 2022, 322, C370-C381.	4.6	4
121	Pilot study of novel lab methodology and testing of platelet function in adolescent women with heavy menstrual bleeding. Pediatric Research, 2018, 83, 693-701.	2.3	3
122	Effect of Pneumatic Tubing System Transport on Platelet Apheresis Units. Cardiovascular Engineering and Technology, 2018, 9, 515-527.	1.6	3
123	Evaluation of the Antihemostatic and Antithrombotic Effects of Lowering Coagulation Factor VII Levels in a Non-human Primate. Cellular and Molecular Bioengineering, 2020, 13, 179-187.	2.1	2
124	Droplet Microfluidics with Reagent Micromixing for Investigating Intrinsic Platelet Functionality. Cellular and Molecular Bioengineering, 2021, 14, 223-230.	2.1	2
125	Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. Blood, 2020, 136, 23-24.	1.4	2
126	Antibodies to Human Factor XII with Antithrombotic Properties. Blood, 2012, 120, 1106-1106.	1.4	2

#	Article	IF	CITATIONS
127	Identification of Qualitative Platelet Disorders in Adolescent Women with Heavy Menstrual Bleeding. Blood, 2016, 128, 4922-4922.	1.4	2
128	Platelet integrin activation surfs the calcium waves. Platelets, 2021, 32, 437-439.	2.3	2
129	Critical Behavior of Subcellular Density Organization During Neutrophil Activation and Migration. Cellular and Molecular Bioengineering, 2015, 8, 543-552.	2.1	1
130	FXII Promotes Coagulation in a FXI and FIX Independent Manner. Blood, 2012, 120, 3362-3362.	1.4	1
131	Development of Coagulation Factor Probes for the Identification of Procoagulant Circulating Tumor Cells. Blood, 2012, 120, 634-634.	1.4	1
132	Apple Domain-Specific Anti-Factor XI Antibodies Inhibit Venous-Type Thrombosis with Improved Hemostatic Safety Profiles Compared to Enoxaparin in Primates. Blood, 2011, 118, 1173-1173.	1.4	1
133	A theme series on Physical Biology in Cancer in AJP-Cell. American Journal of Physiology - Cell Physiology, 2014, 306, C77-C77.	4.6	Ο
134	Bleeding TAPs out. Journal of Thrombosis and Haemostasis, 2019, 17, 247-249.	3.8	0
135	A Theme Series on Emerging Technologies for Use in the Study, Diagnosis and Treatment of Patients with COVID-19. Cellular and Molecular Bioengineering, 2020, 13, 247-248.	2.1	Ο
136	The Leech Product Saratin Is a Potent Inhibitor of Both VWF and Integrin α2β1 Binding to Collagen Blood, 2006, 108, 3928-3928.	1.4	0
137	Factor XI Inhibitor Antibody Treatment Improves Survival In a Murine Polymicrobial Sepsis Model. Blood, 2010, 116, 820-820.	1.4	Ο
138	Coagulation Factors XIa and XIIa Modulate Neutrophil Elastase Release,. Blood, 2011, 118, 3220-3220.	1.4	0
139	Spatial Separation of TF-Carriers Modulates Procoagulant Activity of Circulating TF. Blood, 2011, 118, 2265-2265.	1.4	Ο
140	Exogenous modification of platelet membranes with the omegaâ€3 fatty acids DHA and EPA impairs thrombogenesis. FASEB Journal, 2012, 26, 1016.5.	0.5	0
141	p21-Activated Kinases Regulate Directional Migration and Cytoskeletal Organization in Human Neutrophils. Blood, 2012, 120, 834-834.	1.4	Ο
142	Development Of a Novel Method To Assess Neonatal Platelet Function. Blood, 2013, 122, 4740-4740.	1.4	0
143	E-WE Thrombin (ProCase) Inhibits Thrombin Mediated TAFI Activation and Accelerates TPA-Induced Thrombolysis. Blood, 2016, 128, 1390-1390.	1.4	0
144	Tyrosine Kinase Inhibitors (TKIs) Targeting Syk and BTK Signaling Differentially Affect PI3K Signalosome Organization and Platelet Function. Blood, 2019, 134, 2074-2074.	1.4	0

#	Article	IF	CITATIONS
145	Cardiac Myosin Acts Is a Potent Procoagulant in Vitro and In Vivo. Blood, 2019, 134, 3632-3632.	1.4	0
146	Skeletal Muscle Myosin Is Procoagulant By Binding Factor XI Via Its A3 Domain and Enhancing Factor XI Activation By Thrombin. Blood, 2021, 138, 441-441.	1.4	0